-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is highly heterogeneous, and high-risk multiple myeloma (HRMM) often has a poor prognosis.
Professor Liu Yan
Deputy Director of the First Department of Hematology, Zibo Central Hospital, Deputy Chief Physician
Member of the Hematologist Branch of Shandong Medical Doctor Association
Member of the Hematology and Tumor Professional Committee of Shandong Anti-Cancer Association
Member of the Hematology Professional Committee of Shandong Geriatrics Association
Member of Blood Immunity Branch of Shandong Society of Immunology
Chairman of the Blood Professional Committee of Zibo Geriatrics Association
A patient with HRMM treated with VRd regimen (bortezomib, lenalidomide, dexamethasone) developed adverse events such as rash and peripheral neuritis
In recent years, with the continuous launch of new drugs, the overall prognosis of MM patients has improved significantly, but HRMM patients are prone to progression and have poor prognosis, and more effective individualized treatment regimens are urgently needed
references
[1] Manda S, et al.
Edit: Moon Reviewer: Janet Typesetting: siqili Execution: siqili
"
Click "Read the original text" at the end of the article to view the full content